Free Trial
NASDAQ:ICAD

iCAD Q1 2025 Earnings Report

iCAD logo
$3.50 +0.02 (+0.43%)
Closing price 03:58 PM Eastern
Extended Trading
$3.50 +0.00 (+0.14%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iCAD EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

iCAD Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.54 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iCAD Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iCAD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iCAD and other key companies, straight to your email.

About iCAD

iCAD (NASDAQ:ICAD) engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

View iCAD Profile

More Earnings Resources from MarketBeat